New Protein Risk Predicts Mortality Risk in Heart Failure Patients
Posted on 02 Jan 2024
Heart failure (HF) is a complex clinical condition characterized by high mortality rates. Existing methods for assessing the biological complexity of HF and determining clinical strategies are somewhat inadequate. High-throughput proteomics has the potential to enhance risk prediction; however, its practical application in managing HF patients requires robust validation and proven clinical advantages. Now, researchers have developed a new protein risk score that offers improved calibration and the potential to assist healthcare providers in more accurately determining the mortality risk in individuals with HF.
Researchers from the National Institutes of Health (NIH, Bethesda, MD, USA) have developed and validated a protein risk score to stratify mortality risk in persons with heart failure using a community-based cohort of 7,289 plasma proteins in 1,351 patients with HF using the SomaScan Assay from SomaLogic (Boulder, CO, USA). In the development cohort, the team chose 38 unique proteins for inclusion in the protein risk score. This score showed good calibration, was particularly effective at reclassifying mortality risk at the extremes of the risk spectrum, and outperformed traditional clinical models in terms of clinical utility.
The research highlights the significant potential of the clinical utility of large-scale proteomic assays in improving risk prediction in HF. The tool could guide clinicians in identifying patients who may benefit from intensified medication management or those at high risk for adverse events who might need mechanical circulatory support or transplantation. Nonetheless, the predominance of participants of European descent in the study raises questions about the score's applicability across various demographics. Therefore, additional research is essential to assess the score's effectiveness in diverse populations and to establish specific risk thresholds for various medical interventions.